Abstract: The present disclosure is directed to an online or mobile application for playing a location-based multiplayer game. In one configuration and by non-limiting example, the game is a cross-platform, location-based, massively-multiplayer game of strategy. Players interact to capture millions of battle zones that correspond to real world locations in hundreds of countries using their mobile devices, web browsers, and consoles.

Abstract: The present invention relates to a combination of botulinum toxin and hyaluronic acid for use in the radiation treatment of cancer. The present invention also relates to a method for treating prostate cancer in a human patient, whereby one or more tumours in the prostate are shrunk, inhibited and/or dissolved and the rectum is protected from a subsequent radiation treatment step. Furthermore, the present invention relates to one or more compounds selected from botulinum toxin, hyaluronic acid and a combination of botulinum toxin and hyaluronic acid for use in the treatment of prostate cancer in a human patient by a method whereby one or more tumours in the prostate are shrunk, inhibited and/or dissolved and the rectum is protected from a subsequent radiation treatment step.

Abstract: The present disclosure is directed to an online or mobile application for playing a location-based multiplayer game. In one configuration and by non-limiting example, the game is a cross-platform, location-based, massively-multiplayer game of strategy. Players interact to capture millions of battle zones that correspond to real world locations in hundreds of countries using their mobile devices, web browsers, and consoles.

Abstract: The present disclosure is directed to an online or mobile application for playing a location-based multiplayer game. In one configuration and by non-limiting example, the game is a cross-platform, location-based, massively-multiplayer game of strategy. Players interact to capture millions of battle zones that correspond to real world locations in hundreds of countries using their mobile devices, web browsers, and consoles.

Abstract: The present disclosure is directed to an online or mobile application for playing a location-based multiplayer game. In one configuration and by non-limiting example, the game is a cross-platform, location-based, massively-multiplayer game of strategy. Players interact to capture millions of battle zones that correspond to real world locations in hundreds of countries using their mobile devices, web browsers, and consoles.

Abstract: A composition, medicament or use, comprising or consisting of botulinum toxin type A2 and a surfactant, having one or more or all of the characteristics selected from the group consisting of; (a) a much longer duration of action; (b) a much faster rate of onset of muscular paralysis; (c) a significantly greater intramuscular safety margin; (d) a selective action on inhibition of skeletal muscle contraction; (e) a selective action on inhibition of pain-related (nociceptive) nerve cell function: Wherein each characteristic is determined comparative to the same characteristic effect of botulinum toxin type A1.

Abstract: A composition, medicament or use, comprising or consisting of botulinum toxin type A2 and a surfactant, having one or more or all of the characteristics selected from the group consisting of; (a) a much longer duration of action; (b) a much faster rate of onset of muscular paralysis; (c) a significantly greater intramuscular safety margin; (d) a selective action on inhibition of smooth muscle contraction; (e) a selective action on inhibition of pain-related (nociceptive) nerve cell function: Wherein each characteristic is determined comparative to the same characteristic effect of botulinum toxin type A1.

Abstract: A composition, medicament or use, comprising or consisting of botulinum toxin type A2 and a surfactant, having one or more or all of the characteristics select from the group consisting of; (a) a much longer duration of action; (b) a much faster rate of onset of muscular paralysis; (c) a significantly greater intramuscular safety margin; (d) a selective action on inhibition of skeletal muscle contraction; (e) a selective action on inhibition of pain-related (nociceptive) nerve cell function: Wherein each characteristic is determined comparative to the same characteristic effect of botulinum toxin type A1.